Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

@article{Asami2011GefitinibAF,
  title={Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.},
  author={Kazuhiro Asami and Tomonobu Koizumi and Kazuya Hirai and Shingo Ameshima and Akihiro Tsukadaira and Nobutoshi Morozumi and Akio Morikawa and Shinji Atagi and Masaaki Kawahara},
  journal={Clinical lung cancer},
  year={2011},
  volume={12 6},
  pages={387-92}
}
UNLABELLED Efficacy of first-line gefitinib for elderly epidermal growth factor receptor mutated patients with lung adenocarcinoma is uncertain. This study was aimed to investigate efficacy of gefitinib for such population. The primary endpoint was response rate (RR) and at least 12 cases were needed. Overall RR was 59% (95% confidence interval, 33%-81%) and first-line gefitinib was effective for elderly patients. INTRODUCTION Feasibility of gefitinib therapy in elderly patients with non… CONTINUE READING